Cereno Scientific announces milestone has been reached as part of preclinical CS014 program
Cereno Scientific (XSAT: CRNO B) today announced that the progress made in preclinical program CS014 has triggered an undisclosed milestone payment to Emeriti Bio from which CS014 was acquired in 2019. CS014 is currently undergoing a preclinical development program in collaboration with the University of Michigan. Based on this progress a new patent application has been filed.“When we acquired the CS014 program from Emeriti Bio back in 2019 we thought it was a good complement to our CVD portfolio showing exciting innovative properties. As we have continued its development our belief in this